Related Experiment Video

Updated: Jun 18, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

DPPA inhibits melanoma by targeting angiogenesis through activating autocrine IFN-γ-CXCL9/10/11-CXCR3 axis in

Zelong Wang1, Zibei Feng1, Chunhui Huang1

  • 1School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, China.

Iscience
|June 17, 2026
PubMed

Insights

Dipalmitoylphosphatidic acid (DPPA) effectively suppresses malignant melanoma growth and metastasis by inhibiting tumor angiogenesis. This novel approach offers a promising alternative to existing therapies with fewer side effects.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Antiangiogenic therapy is a key strategy for malignant melanoma (MM).
  • Bevacizumab, a VEGF inhibitor, has significant side effects.
  • Novel antiangiogenic agents are needed for MM treatment.

Purpose of the Study:

  • To investigate the antiangiogenic potential of Dipalmitoylphosphatidic acid (DPPA) in malignant melanoma.
  • To elucidate the mechanism by which DPPA affects MM tumor development.

Main Methods:

  • In vitro and in vivo models of malignant melanoma.
  • Assessment of tumor growth, metastasis, and angiogenesis.
  • Analysis of signaling pathways including interferon gamma (IFN-γ) and CXCL9/10/11-CXCR3.

Main Results:

  • DPPA significantly suppressed MM tumor growth and metastasis.
  • DPPA inhibited tumor angiogenesis but not cell proliferation or invasion.
  • DPPA's mechanism involves regulating IFN-γ and CXCL9/10/11-CXCR3 signaling.

Conclusions:

  • DPPA demonstrates potent antiangiogenic activity in malignant melanoma.
  • DPPA represents a potential novel therapeutic agent for MM.
  • DPPA's mechanism of action provides insights into antiangiogenic strategies.
Keywords:
health sciences

More Related Videos

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models05:33

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Published on: September 6, 2024

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...